RNA is unstable and cumbersome, and just getting it into the body without having it break down is difficult. Once that hurdle is met, there is another: the vast majority of the drug is taken up by the liver. Many current RNA-based approaches turn this apparent bug into a strength, because they seek to treat liver diseases. 

But what if you need to deliver RNA somewhere besides the liver?

Biomedical engineer Hanjoong Jo’s lab at Emory/Georgia Tech, working with Katherine Ferrara’s group at UC Davis, has developed technology to broaden the liver-dominant properties of RNA-based drugs.

The results were recently published in ACS Nano. The researchers show they can selectively target an anti-microRNA agent to inflamed blood vessels in mice while avoiding other tissues.

“We have solved a major obstacle of using anti-miRNA as a therapeutic by being able to do a targeted delivery to only inflamed endothelial cells while all other tissues examined, including liver, lung, kidney, blood cells, spleen, etc. showed no detectable side-effects,” Jo says.

Research by Jo’s lab, published in 2013 in Nature Communications, had established that microRNA 712 was a master controller of inflammation in atherosclerosis.

In the Nature Communications paper, an antisense molecule that counteracts miRNA 712 can stop the effects of high fat diet and disturbed blood flow in the atherosclerosis model. It reaches the desired cells: endothelial cells, which line blood vessels. But the anti-miRNA has significant effects on the liver and blood cells at the same time.

To restrict delivery of an antisense molecule countering miRNA 712 to endothelial cells, the authors built nanoparticles with several layers. Inside was the payload: the anti-miRNA, packaged with a positively charged lipid. Around that is a neutral coating, decorated with a peptide that targets the inflammatory molecule vascular cell adhesion molecule 1. The same peptide has previously been tested as a potential cardiovascular imaging tool.

The resulting multi-layer package was delivered selectively to only the inflamed endothelial cells, the authors show in the ACS Nano paper. In the atherosclerosis mouse model, it was possible to use five times less than the “naked” untargeted version and still see beneficial effects.

The multi-layer packaging method could easily be adapted to other miRNAs, such as the human equivalent miR-205, in the context of treating atherosclerosis. However, using other targeting peptides, with the goal of reaching other tissues, would be a bigger stretch.

Hanjoong Jo is the associate chair and John and Jan Portman Professor of Biomedical Engineering in the Wallace H. Coulter Department of Biomedical Engineering at Georgia Tech and Emory. 

Media Contacts:

Walter Rich
Communications Manager
Wallace H. Coulter Department of Biomedical Engineering
Georgia Institute of Technology

Quinn Eastman   
Research Communications
Woodruff Health Sciences Center
Emory University